The herpesvirus proteases as targets for antiviral chemotherapy

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 1, 2000, Pages 1-22

  Waxman, Lloyd ^a   Darke, Paul L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytomegalovirus; Dimerization; Drug design; Herpes simplex virus; Herpesvirus; Inhibitor; Proteinase; Serine protease

Indexed keywords

ANTIVIRUS AGENT; CARBONYL DERIVATIVE; OMEPRAZOLE; SERINE PROTEINASE; VIRUS ENZYME;

BIOCHEMISTRY; CYTOMEGALOVIRUS; DIMERIZATION; DNA VIRUS; DRUG TARGETING; ENZYME ACTIVE SITE; HERPES SIMPLEX; HERPES VIRUS; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 0033972803     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100101     Document Type: Review

References (121)

1. Abood NA, Schretzman LA, Flynn DL, Houseman KA, Wittwer AJ, Dilworth VM, Hippenmeyer PJ & Holwerda BC (1997) Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture. Bioorganic and Medicinal Chemistry Letters 7:2105-2108.
2. Apeler H, Gottschalk U, Guntermann D, Hansen J, Massen J, Schmidt E, Schneider K-H, Schneidereit M & Rubsamen-Waigmann H (1997) Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein. European Journal of Biochemistry 247:890-895.
3. Arvin AM (1996) Varicella-zoster virus: overview and clinical manifestations. Seminars in Dermatology 15:4-7.
4. Baum EZ, Bebernitz GA, Hulmes JD, Muzithras VP, Jones TR & Gluzman Y (1993) Expression and analysis of the human cytomegalovirus UL80-encoded protease: identification of autoproteolytic sites. Journal of Virology 67:497-506.
5. 33phosphorous. Analytical Biochemistry 237:129-134.
6. Baum EZ, Siegel MM, Bebernitz GA, Hulmes JD, Sridharan L, Sun L, Tabei K, Johnston SH, Wildey MJ, Nygaard J, Jones TR & Gluzman Y (1996b) Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. Biochemistry 35:5838-5846.
7. Baum EZ, Ding W-D, Siegel MM, Hulmes J, Bebernitz GA, Sridharan L, Tabei K, Krishnamurthy G, Carofiglio T, Groves JT, Bloom JD, DiGrandi M, Bradley M, Ellestad G, Seddon AP & Gluzman Y (1996c) Flavins inhibit cytomegalovirus protease UL80 protease via disulfide bonc formation. Biochemistry 35:5847-5855.
8. Bonneau PR, Grand-Maitre C, Greenwood DJ, Lagace L, LaPlante SR, Massariol M-J, Ogilvie WW, O'Meara JA & Kawai SH (1997) Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors. Biochemistry 36:12644-12652.
9. Bonneau PR, Plouffe C, Pelletier A, Wernic D & Poupart M-C (1998) Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies. Analytical Biochemistry 255:59-65.
10. Bonneau PR, Hasani F, Plouffe C, Malenfant E, LaPlante SR, Guse I, Ogilvie WW, Plante R, Davidson WC, Hopkins JL, Morelock MM, Cordingley MG & Deziel R (1999) Inhibition of human cytomegalovirus protease by monocyclic β-lactam derivatives: kinetic characterization using a fluorescent probe. Journal of the American Chemical Society 121:2965-2973.
11. Borthwick AD, Weingarten G, Haley TM, Tomaszewski M, Wang W, Hu Z, Bedard J, Jin H, Yuen L & Mansour TS (1998) Design and synthesis of monocyclic β-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Bioorganic and Medicinal Chemistry Letters 8:365-370.
12. Britt WJ & Alford CA (1996) Cytomegalovirus. In Fields Virology, 3rd Edition, pp. 2493-2523. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott-Raven.
13. Burck PJ, Berg DH, Luk TP, Sassmannshausen LM, Wakulchik M, Smith DP, Hsiung HM, Becker GW, Gibson W & Villarreal EC (1994) Human cytomegalovirus rnaturational proteinase: expression in Eschericia coli, purification, and enzymatic characterization by using peptide mimics of natural cleavage sites. Journal of Virology 68:2937-2946.
14. Casjens S & King J (1975) Virus assembly. Annual Reviews of Biochemistry 44:555-611.
15. Castillo MJ, Nakajima K, Zimmerrnan M & Powers JC (1979) Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases. Analytical Biochemistry 99:53-64.
16. Chen P, Tsuge H, Almassy RJ, Gribskov CL, Katoh S, Vanderpooi DL, Margosiak SA, Pinko C, Matthews DA & Kan C-C (1996) Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 86:835-843.
17. Chu M, Mierzwa R, Truumees I, King A, Patel M, Pichardo J, Hart A, Dasmahapatra B, Das PR & Puar (1996) Sch 65676: a novel fungal metabolite with the inhibitory activity against the cytomegalovirus protease. Tetrahedron Letters 37:3943-3946.
18. Cole JL (1996) Characterization of human cytomegalovirus protease dimerization by analytical centrifugation. Biochemistry 35:15601-15610.
19. Corey L, Adams HG, Brown ZA & Holmes KK (1983) Genital herpes simplex virus infections: clinical manifestations, course and complications. Annals of Internal Medicine 98:958-972.
20. Cox GA, Wakulchik M, Sassmannshausen LM, Gibson W & Villarreal EC (1995) Human cytomegalovirus proteinase: candidate glutamic acid identified as third member of putative activesite triad. Journal of Virology 69:4524-4528.
21. Craik CS, Roczniak S, Largman C & Rutter WJ (1987) The catalytic role of the active site aspartic acid in serine proteases. Science 237:909-913.
22. Darke PL (1994) Stability of dimeric retroviral proteases. Methods in Enzymology 241:104-127.
23. Darke PL & Kuo LC (1998) Low temperature assay for active HCMV protease in dimeric form. US Patent No. 5891661.
24. Darke PL, Chen E, Hall DL, Sardana MK, Veloski CA, Lafemina RL, Shafer JA & Kuo LC (1994) Purification of active herpes simplex virus 1 protease expressed in Escherichia coli. Journal of Biological Chemistry 269:18708-18711.
25. Darke PL, Cole JL, Waxman L, Hall DL, Sardana MK & Kuo LC (1996) Active human cytomegalovirus protease is a dimer. Journal of Biological Chemistry 271:7445-7449.
26. 0 with monocyclic β-lactams. Bioorganic and Medicinal Chemistry letters 8:1437-1442.
27. DiIanni CL, Mapelli C, Drier DA, Tsao J, Natarajan S, Riexinger D, Festin SM, Bolgar M, Yamanaka G, Weinheimer SP, Meyers CA, Colonno RJ & Cordingley MG (1993) In vitro activity of the herpes simplex virus type 1 protease with peptide substrates. Journal of Biological Chemistry 268:25449-25454.
28. DiIanni CL, Stevens JT, Bolgar M, O'Boyle II DR, Weinheimer SP & Colonno RJ (1994) Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. Journal of Biological Chemistry 269:12672-12676.
29. Donaghy G & Jupp R (1995) Characterization of the Epstein-Barr virus proteinase and comparison with the human cytomegalovirus proteinase. Journal of Virology 69:1265-1270.
30. Fahrney DE & Gold AM (1963) Sulfonyl fluorides as inhibitors of esterases. I. Rates of reaction with acetylcholinesterase, chymotrypsin, and trypsin. Journal of the American Chemical Society 85:997-1000.
31. Fields BN, Knipe DM & Howley PM (1996) Fields Virology, 3rd Edition. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott-Raven.
32. Finke PE, Shah SK, Fletcher DS, Ashe BM, Brause KA, Chandelier GO, Dellea PS, Hand KM, Maycock AL, Osinga DG, Underwood DJ, Weston H, Davies P & Doherty JB (1995) Orally active β-lactam inhibitors of human leukocyte elastase. Stereospecific synthesis and structure-activity relationships for 3,3′-dialkylazetidin-2-ones. Journal of Medicinal Chemistry 38:2449-2462.
33. Flynn DL, Abood NA & Holwerda BC (1997) Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases. Current Opinion in Chemical Biology 1:190-196.
34. Gao M, Matusick-Kumar L, Hurlburt W, DiTusa SF, Newcomb WW, Brown JC, McCann III PJ, Deckman I & Colonno RJ (1994) The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. Journal of Virology 68:3702-3712.
35. Gibson W (1996) Structure and assembly of the virion. Intervirology 39:389-400.
36. Gibson W & Hall MRT (1997) Assemblin, an essential herpesvirus proteinase. Drug Design and Discovery 15:39-47.
37. Gibson W & Roizman B (1972) Proteins specified by herpes simplex virus. VIII. Characterization and composition of multiple capsid forms of subtypes 1 and 2. Journal of Virology 10:1044-1052.
38. Gibson W & Roizman B (1974) Proteins specified by herpes simplex virus - X. Staining and radiolabelling properties of B capsid and virion proteins in polyacrylamide gels. Journal of Virology 13:155-165.
39. Godefroy S & Guenet C (1995) Autoprocessing of HSV-1 protease: effect of deletions on autoproteolysis. FEBS Letters 357:168-172.
40. Hall DL & Darke PL (1995) Activation of the herpes simplex virus type 1 protease. Journal of Biological Chemistry 270:22697-22700.
41. Hall MRT & Gibson W (1996) Cytomegalovirus assemblin: the amino and carboxyl domains of the proteinase form active enzyme when separately cloned and coexpressed in eukaryotic cells. Journal of Virology 70:5395-5404.
42. Handa BK, Keech E, Conway EA, Broadhurst A & Ritchie A (1995) Design and synthesis of a quenched fluorogenic peptide substrate for human cytomegalovirus proteinase. Antiviral Chemistry and Chemotherapeutics 6:255-261.
43. Harper JW, Cook RR, Roberts CJ, Mclaughlin BJ & Powers JC (1984) Active site mapping of the serine proteases human leucocyte elastase, cathepsin G, porcine pancreatic elastase, rat mast cell proteases I and II, chymotrypsin Aα, and Staphylococcus aureus protease V-8 using tripeptide thiobenzyl ester substrates. Biochemistry 23:2995-3002.
44. Harper JW, Hemmi K & Powers JC (1985) Reaction, of serine proteases with substituted coumarins: discovery of 3,4-dichloroiso-coumarin, a new general mechanism based serine protease inhibitor. Biochemistry 24:1831-1841.
45. Higgins DL, Lewis SD & Shafer JA (1983) Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. Journal of Biological Chemistry 258:9276-9282.
46. Holskin BP, Bukhtiyarova M, Dunn BM, Baur P, deChastonay J & Pennington MW (1995) A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Analytical Biochemistry 227:148-155.
47. Holwerda BC (1997) Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Research 35:1-21.
48. Holwerda BC, Wittwer AJ, Duffin IL, Smith C, Toth MV, Carr LS, Wiegand RC & Bryant ML (1994) Activity of two-chain recombinant human cytomegalovirus protease. Journal of Biological Chemistry 269:25911-25915.
49. Hoog SS, Smith WW, Qiu X, Janson CA, Hellmig B, McQueney MS, O'Donnell K, O'Shannessy D, DiLella AG, Debouck C & Abdel-Meguid SS (1997) Active site cavity of herpesvirus proteases revealed by the crystal structure of herpes simplex virus protease/inhibitor complex. Biochemistry 36:14023-14029.
50. Jarvest RL, Parratt MJ, Debouck CM, Gorniak JG, Jennings LJ, Serafinowska HT & Strickler JE (1996) Inhibition of HSV-1 protease by benzoxazinones. Bioorganic and Medicinal Chemistry Letters 6:2463-2466.
51. Jarvest RL, Connor SC, Gorniak JG, Jennings LJ, Serafinowska HT & West A (1997) Potent selective thienoxazinone inhibitors of herpes proteases. Bioorganic and Medicinal Chemistry Letters 7:1733-1738.
52. Jarvest RL, Pinto IL, Ashman SM, Dabrowski CE, Fernandez AV, Jennings LJ, Lavery P & Tew DG (1999) Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones. Bioorganic and Medicinal Chemistry Letters 9:443-448.
53. Jones TR, Sun L, Bebernitz GA, Muzithras VP, Kim HJ, Johnston SH & Baum EZ (1994) Proteolytic activity of human cytomegalovirus UL80 protease cleavage site mutants. Journal of Virology 68:3742-3752.
54. Krantz A, Spencer RW, Tam TF, Liak TJ, Copp LJ, Thomas EM & Rafferty SP (1990) Design and synthesis of 4H-3,1-benzoxazin-4-ones as potent alternate substrate inhibitors of human leucocyte elastase. Journal of Medicinal Chemistry 33:464-479.
55. Krausslich H-G (1991) Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proceedings of the National Academy of Sciences, USA 88:3213-3217.
56. Krausslich H-G (1992) Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. Journal of Virology 66:567-572.
57. LaFemina RL, Bakshi K, Long WJ, Pramanik B, Veloski CA, Wolanski B, Marcy AI & Hazuda DJ (1996) Characterization of a soluble stable human cytomegalovirus protease and inhibition by M site peptide mimics. Journal of Virology 70:4819-4824.
58. LaPlante SR, Aubry N, Bonneau PR, Cameron DR, Lagace L, Massariol M-J, Montpetit H, Plouffe C, Kawai SH, Fulton BD, Chen Z & Ni F (1998) Human cytomegalovirus protease complexes its substrate recognition sequences in an extended peptide conformation. Biochemistry 37:9793-9801.
59. LaPlante SR, Bonneau PR, Aubry N, Cameron DR, Deziel R, Grand-Maitre C, Plouffe C, Tong L & Kawai SH (1999) Characterization of the human cytomegalovirus protease as an induced-fit serine protease and the implications to the design of mechanism-based inhibitors. Journal of the American Chemical Society 121:2974-2986.
60. Levy JA (1997) Three new human herpesviruses (HHV6, 7, and 8). Lancet 349:558-562.
61. Liang P-H, Brun KA, Feild JA, O'Donnell K, Doyle ML, Green SM, Baker AE, Blackburn MN & Abdel-Meguid SS (1998) Site-directed mutagenesis probing the catalytic role of arginines 165 and 166 of human cytomegalovirus protease. Biochemistry 37:5923-5929.
62. Lin C & Rice CM (1995) The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proceedings of the National Academy of Sciences, USA 92:7622-7626.
63. Lindberg P, Brandstrom A & Wallmark B (1987) Structure-activity relationships of omeprazole analogues and their mechanism of action. Trends in Pharmacological Science 8:399-402.
64. Liu F & Roizman B (1991a) The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. Journal of Virology 65:5149-5156.
65. Liu F & Roizman B (1991b) The promoter, transcriptional unit, and coding sequence of herpes simplex virus 1 family 35 proteins are contained within and in frame with the UL26 open reading frame. Journal of Virology 65:206-212.
66. Liu F & Roizman B (1992) Differentiation of multiple domains in the herpes simplex virus 1 protease encoded by the UL26 gene. Proceedings of the National Academy of Sciences, USA 89:2076-2080.
67. Liu F & Roizman B (1993) Characterization of the protease and other products of amino-terminus-proximal cleavage of the herpes simplex virus 1 UL26 protein. Journal of Virology 67:1300-1309.
68. McCann PJ, O'Boyle II DR & Deckman IC (1994) Investigation of the specificity of the herpes simplex virus 1 protease by point mutagenesis of the autoproteolysis sites. Journal of Virology 68:526-529.
69. Mangel WF, McGrath WJ, Toledo DL & Anderson CW (1993) Viral DNA and a viral peptide can act as cofactors of adenovirus virion proteinase activity. Nature 361:274-275.
70. Margosiak SA, Vanderpool DL, Sisson W, Pinko C & Kan C-C (1996) Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homo-dimer. Biochemistry 35:5300-5307.
71. Matusick-Kumar L III PJM, Robertson BJ, Newcomb WW, Brown JC & Gao M (1995) Release of the catalytic domain NO from the herpes simplex virus type 1 protease is required for viral growth. Journal of Virology 69:7113-7121.
72. Meek TD, Rodriguez EJ & Angeles TS (1994) Use of steady state kinetic methods to elucidate the kinetic and chemical mechanisms of retroviral proteases. Methods in Enzymology 241:127-156.
73. Mehdi S (1993) Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorganic Chemistry 21:249-259.
74. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL & Springer JP (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615-620.
75. O'Boyle II DR, Wager-Smith K, Stevens III JT & Weinheimer SP (1995) The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain. Journal of Biological Chemistry 270:4753-4758.
76. O'Boyle II DR, Pokornowski KA, McCann III PJ & Weinheimer SP (1997) Identification of a novel peptide substrate of HSV-1 protease using substrate phage display. Virology 236:338-347.
77. Ogilvie W, Bailey M, Poupart M-A, Abraham A, Bhavsar A, Bonneau P, Bordeleau J, Bousquet Y, Chabot C, Duceppe J-S, Fazal G, Goulet S, Grand-Maitrs C, Guse I, Halmos T, Lavallee P, Leach M, Malenfant E, O'Meara J, Plante R, Plouffe C, Poirier M, Soucy F, Yoakim C & Deziel R (1997) Peptidomimetic inhibitors of the human cytomegalovirus protease. Journal of Medicinal Chemistry 40:4113-4135.
78. Pinko C, Margosiak SA, Vanderpool D, Gutowski JC, Condon B & Kan C-C (1995) Single-chain recombinant human cytomegalovirus protease. Journal of Biological Chemistry 270:23634-23640.
79. Pinto IL, West A, Debouck CM, DiLella AG, Gorniak JG, O'Donnell KC, O'Shannessy DJ, Patel A & Jarvest RL (1996) Novel, selective mechanism-based inhibitors of the herpes proteases. Bioorganic and Medicinal Chemistry Letters 6:2467-2472.
80. Pinto IL, Jarvest RL, Clarke B, Dabrowski CE, Fenwick A, Gorczyca MM, Jennings LJ, Lavery P. Sternberg EJ, Tew DG & West A (1999) Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism. Bioorganic and Medicinal Chemistry Letters 9:449-452.
81. Preston VG, Coates JAV & Rixon FJ (1983) Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA. Journal of Virology 45:1056-1064.
82. Qian-Cutrone J, Kolb JM, McBrien K, Huang S, Gustavson D, Lowe SE & Manly SP (1998) Quanolirones I and II, two new human cytomegalovirus protease inhibitors produced by Streptomyces sp. WC76535. Journal of Natural Products 61:1379-1382.
83. Qiu X, Culp JS, DiLella AG, Hellmig B, Hoog SS, Janson CA, Smith WW & Abdel-Meguid SS (1996) Unique fold and active site in cytomegalovirus protease. Nature 383:275-279.
84. Qiu X, Janson CA, Culp JS, Richardson SB, Debouck C, Smith WW & Abdel-Meguid SS (1997) Crystal structure of varicellazoster virus protease. Proceedings of the National Academy of Sciences, USA 94:2874-2879.
85. Radhakrishnan R, Presta LG, Meyer EF Jr & Wildonger R (1987) Crystal structures of the complex of porcine pancreatic elastase with two valine-derived benzoxazinone inhibitors. Journal of Molecular Biology 198:417-424.
86. Register RB & Shafer JA (1997) Alteration in catalytic activity and virus maturation produced by mutation of the conserved histidine residues of herpes simplex virus type 1 protease. Journal of Virology 71:8572-8581.
87. Rickinson AB & Kieff E (1996) Epstein-Barr Virus. In Fields Virology, 3rd Edition, pp. 2397-2446. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott-Raven.
88. Robertson BJ, McCann III PJ, Matusick-Kumar L, Newcomb WW, Brown JC, Colonno RJ & Gao M (1996) Separate functional domains of the herpes simplex virus type 1 protease; evidence for cleavage inside capsids. Journal of Virology 70:4317-4328.
89. Roizman B & Sears AE (1996) Herpes simplex viruses and their replication. In Fields Virology, 3rd Edition, pp. 2231-2296. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott-Raven.
90. Sali A, Veerapandian B, Cooper JB, Moss DS, Hofmann T & Blundell TL (1992) Domain flexibility in aspartic proteinases. Proteins: Structure, Function, and Genetics 12:158-170.
91. Salvesen G & Nagase H (1989) Inhibition of proteolytic enzymes. In Proteolytic Enzymes, pp. 83-104. Edited by RJ Beynon & JS Bond. Oxford: IRL Press.
92. Sardana VV, Wolfgang JA, Veloski CA, Long WJ, LeGrow K, Wolanski B, Emini EA & LaFemina RL (1994) Peptide substrate cleavage specificity of the human cytomegalovirus protease. Journal of Biological Chemistry 269:14337-14340.
93. Schmidt U & Darke PL (1997) Dimerization and activation of the herpes simplex virus type 1 protease. Journal of Biological Chemistry 272:7732-7735.
94. Schrag JD, Prasad BW, Rixon RJ & Chiu W (1989) Three dimensional structure of the HSV-1 nucleocapsid. Cell 56:651-660.
95. Shah KS, Dorn CP, Finke PE, Hale JJ, Hagmann WK, Brause KA, Chandler, GO, Kissinger AL, Ashe BM, Weston H, Knight WB, Maycock AL, Dellea PS, Fletcher DS, Hand KM, Mumford RA, Underwood DJ & Doherty JB (1992) Orally active β-lactam inhibitors of human leucocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones. Journal of Medicinal Chemistry 35:3745-3754.
96. Shieh HS, Kurumbail RG, Stevens AM, Stegeman RA, Sturman EJ, Pak JY, Wittwer AJ, Palmier MO, Wiegand RC, Holwerda BC & Stallings WC (1996) Three-dimensional structure of human cytomegalovirus protease. Nature 383:279-82.
97. Shu Q-Z, Ye Q, Kolb JM, Huang S, Veitch JA, Lowe SE & Manly SP (1997) Bripiodionen, a new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. Journal of Natural Products 60:529-532.
98. Sloan JH, Loutsch JM, Boyce SY & Holwerda BC (1997) Expression and characterization of recombinant murine cytomegalovirus protease. Journal of Virology 71:7114-7118.
99. Stein RL, Strimpler AM, Edwards PD, Lewis JJ, Mauger RC, Schwartz JA, Stein MM, Trainor DA, Wildonger RA & Zottola MA (1987a) Mechanism of slow-binding of human leucocyte elastase by trifluoromethyl ketones. Biochemistry 26:2682-2689.
100. Stein RL, Strimpler AM, Hori H & Powers JC (1987b) Catalysis by human leucocyte elastase: mechanistic insights into specificity requirements. Biochemistry 26:1301-1305.
101. Stevens JT, Mapelli C, Tsao J, Hail M, O'Boyle II C & Weinheimer SP (1994) In vitro proteolytic activity and active-site identification of the human cytomegalovirus protease. European Journal of Biochemistry 226:361-367.
102. Teshima T, Griffin JC & Powers JC (1982) A new class of heterocyclic serine protease inhibitors: inhibition of human leucocyte elastase, porcine pancreatic elastase, cathepsin G, and bovine chymotrypsin A with substituted benzoxazinones, quinazilones, and anthranilates. Journal of Biological Chemistry 257:5085-5091.
103. Thomsen DR, Roof L & Homa FL (1994) Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins. Journal of Virology 68:2442-2457.
104. Tigue NJ & Kay J (1998) Autoprocessing and peptide substrates for human herpesvirus 6 proteinase. Journal of Biological Chemistry 273:26441-26446.
105. Tigue NJ, Matharu PJ, Roberts NA, Mills JS, Kay J & Jupp R (1996) Cloning, expression, and characterization of the proteinase from human herpesvirus 6. Journal of Virology 6:4136-4141.
106. 6 extension: purification, autocatalytic release of the mature enzyme, and biochemical characterization. Protein Expression and Purification 14:343-352.
107. Tong L, Qian C, Massariol M-J, Bonneau PR, Cordingley MG & Lagace L (1996) A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383:272-275.
108. Tong L, Qian C, Massariol M-J, Deziel R, Yoakim C & Lagace L (1998) Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease. Nature Structural Biology 5:819-826.
109. Umezawa H (1976) Structures and activities of protease inhibitors of microbial origin. Methods in Enzymology 45:678-695.
110. Unal A, Pray TR, Lagunoff M, Pennington MW, Ganem D & Craik CS (1997) The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). Journal of Virology 71:7030-7038.
111. Valenzuela P & Bender ML (1971) Kinetic properties of succinylated and ethylenediamine-amidated chymotrypsins. Biochimica et Biophysica Acta 250:538-548.
112. Watanabe S, Konno K, Shigeta S & Yokota T (1998) Inhibition of human cytomegalovirus proteinase by salcomine derivatives. Antiviral Chemistry & Chemotherapy 9:269-274.
113. Webster A, Hay RT & Kemp G (1993) The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell 72:97-104.
114. Weinheimer SP, McCann III PJ, O'Boyle II DR, Stevens JT, Boyd BA, Drier DA, Yamanaka GA, DiIanni CL, Deckman IC & Cordingley MG (1993) Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles. Journal of Virology 67:5813-5822.
115. Welch AR, McNally LM & Gibson W (1991) Cytomegalovirus assembly protein nested gene family: four 3′-coterminal transcripts encode four in-frame, overlapping proteins. Journal of Virology 65:4091-4100.
116. Welch AR, McNally LM, Hall MRT & Gibson W (1993) Herpesvirus proteinase: site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine. Journal of Virology 67:7360-7372.
117. Whitley RJ (1996) Herpes simplex viruses. In Fields Virology, 3rd Edition, pp. 2297-2342. Edited by BN Fields, DM Knipe ′ PM Howley. Philadelphia: Lippincott-Raven.
118. Yamanaka G, DiIanni CL, O'Boyle DR, Stevens J, Weinheimer SP, Deckman IC, Matusick-Kumar L & Colonno RJ (1995) Stimulation of the herpes simplex virus type I protease by antichaeotropic salts. Journal of Biological Chemistry 270:30168-30172.
119. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, DeFrancesco R, Kuo LC & Chen Z (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Science 7:837-847.
120. Yoakim C, Ogilvie WW, Cameron DR, Chabot C, Guse I, Hache B, Naud J, O'Meara JA, Plante R & Deziel R (1998a) β-Lactam derivatives as inhibitors of human cytomegalovirus protease. Journal of Medicinal Chemistry 41:2882-2891.
121. Yoakim C, Ogilvie WW, Cameron DR, Chabot C, Grand-Maitre C, Guse I, Hache B, Kawai S, Naud J, O'Meara JA, Plante R & Deziel R (1998b) Potent β-lactam inhibitors of human cytomegalovirus protease. Antiviral Chemistry & Chemotherapy 9:379-387.